TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria of TB (tuberculosis ) subjects:~* Diagnosis TB ;~* 18 to 65 years ;~* Consent and signed informed consent forms(ICF) ;~* Comply with follow-up .~Exclusion Criteria of TB (tuberculosis ) subjects:~* advanced cancer, diabetes,copd in acute episodes, acute/ progressive liver disease or kidney disease, congestive heart failure, etc ;~* Taking part in other clinical or within 3 months involved in any other clinical;~* histories of allergy ;~* in pregnancy or lactation;~* In a mental illness ;~* Any conditions affect the trial evaluation.~Inclusion Criteria of Non-tuberculosis subjects with lung disease :~* Diagnosis non-tuberculosis subjects with lung disease ;~* 18 to 65 years ;~* Consent and signed signed informed consent forms(ICF) ;~* Comply with follow-up .~Exclusion Criteria of Non-tuberculosis subjects with lung disease :~* advanced cancer, diabetes,copd in acute episodes, acute/ progressive liver disease or kidney disease, congestive heart failure, etc ;~* Taking part in other clinical or within 3 months involved in any other clinical;~* histories of allergy;~* in pregnancy or lactation;~* In a mental illness ;~* Any conditions may affect the trial evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TB subjects (Type: EXPERIMENTAL): 96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
- non-TB subjects with lung disease (Type: ACTIVE_COMPARATOR): 96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Outcomes and Gingival Blood Flow Using Laser Doppler Flowmetry Following the Use of Episil on Free Gingival Graft Donor Sites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient of record at UTHealth School of Dentistry Houston Texas~* signed treatment plan for a FGG~* the ability to provide research informed consent~Exclusion Criteria:~* any allergies to any of the ingredients in episil including allergies to peanuts, soy or peppermint oil~* smokers~* pregnant or breast feeding women~* inability or unwillingness to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- episil wound dressing (Type: EXPERIMENTAL): Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
- PeriAcryl90 wound dressing (Type: ACTIVE_COMPARATOR): PeriAcryl90 is a cyanoacrylate wound dressing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Juvenile Rheumatoid Arthritis or Juvenile Idiopathic Arthritis;~* Current active arthritis;~* Failed treatment with at least one disease modifying anti-rheumatic drug (DMARD);~* Subjects must discontinue use of any DMARD other than methotrexate prior to the first dose of study medication~Exclusion Criteria:~* Presence of infection or history of frequent acute or chronic infections;~* Joint replacement surgery required during the study or history of surgery on more than 5 joints;~* Live vaccines within 3 months of the first dose of study medication;~* Unresolved serious bacterial infection or chronic bacterial infection;~* Subjects who currently have intermittent fever due to JRA/JIA, rheumatoid rash, hepato-splenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: ACTIVE_COMPARATOR): Double Blind Period
- Placebo (Type: PLACEBO_COMPARATOR): Double Blind Period
- Abatacept - Open Label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~General and Dental Health~* Good general and dental health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral examination~* Have no current active caries or periodontal disease that may compromise the study or the health of the subjects~* Residency: Currently living in the Indianapolis, Indiana area~Dentures:~* Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accommodate two enamel specimens (required dimensions 12 mm x 7 mm)~* Willing to have their denture modified to accommodate enamel test specimens and willing and capable of wearing their removable mandibular partial dentures 24 hours per day during the experimental periods~* All restorations in a good state of repair~* Salivary Flow: Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 mL/minute; gum base stimulated whole saliva flow rate ≥ 0.8 mL/minute)~Exclusion Criteria:~* Antibiotics: Use of antibiotics two weeks prior to a treatment visit or anticipated use during the study treatment periods~* Study Scale Use: Subjects unable to measure product weights accurately using the assigned study scale as determined by the study staff (as demonstrated on or before Visit 4)~* A member of the site study staff who is directly working on the project or living in that staff's household~* Any employee of any toothpaste manufacturer or their spouse or family member

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Experimental dentifrice 0.5g, 45 seconds brushing group (Type: EXPERIMENTAL): Participants brush twice a daily for 45 seconds with experimental dentifrice.
- Experimental dentifrice 1.5g, 45 seconds brushing group (Type: EXPERIMENTAL): Participants brush twice a daily for 45 seconds with experimental dentifrice.
- Experimental dentifrice 0.5g, 2 minutes brushing group (Type: EXPERIMENTAL): Participants brush twice a daily for 2 minutes with experimental dentifrice.
- Experimental dentifrice 1.5g, 2 minutes brushing group (Type: EXPERIMENTAL): Participants brush twice a daily for 2 minutes with experimental dentifrice.
- Contol group (Type: ACTIVE_COMPARATOR): Participants brush twice a daily for 2 minutes with controll dentifrice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 24-75 years~* Diagnosed with Diagnostic and Statistical Manual of Mental Disorders (DSM) IV Major Depressive Disorder, nonpsychotic~* 24-item Hamilton Rating Scale for Depression (HRSD) score ≥ 16~* Willing to and capable of providing informed consent and complying with study procedures~* Subjects are right-handed~* Using appropriate contraceptive method if woman of child-bearing age~Exclusion Criteria:~* Current comorbid Axis I DSM IV disorder other than Nicotine Dependence, Adjustment Disorder, Panic Disorder, Generalized Anxiety Disorder, or Social Phobia~* Diagnosis of substance abuse or dependence (excluding Nicotine Dependence) within the past 12 months~* History of psychosis or psychotic disorder, mania or bipolar disorder~* Subject is considered to be at significant risk of suicide based on current mental status and recent history~* History of allergic or adverse reaction to citalopram, or nonresponse to adequate trial of citalopram (at least 4 weeks at dose of 40mg) or escitalopram (at least 4 weeks at dose of 20mg)~* Subject is considered based on history to be unlikely to respond to the single agent citalopram (i.e., subjects with treatment resistant depression)~* Current treatment with psychotherapy~* Clinical Global Impression (CGI)-Severity score of 7 at baseline Clinical Interview~* Current or recent (within the past 4 weeks) treatment with any of the following: antidepressants, antipsychotics, mood stabilizers, isoniazid, glucocorticoids, opiates, centrally active antihypertensive drugs (e.g. clonidine, reserpine)~* Subject has metal in body or prior history working with metal fragments (e.g., as a machinist), tattoos, or unable to tolerate the scanning procedures (i.e., severe obesity, claustrophobia)~* Acute, severe, or unstable medical illness

- Gender: FEMALE
- Minimum Age: 24 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Open Track (Type: ACTIVE_COMPARATOR): Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
- Placebo Track (Type: PLACEBO_COMPARATOR): Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Second Open Label Extension to Bridging Study CTBM100C2303

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed all visits in study CTBM100C2303 and CTBM100C2303E1, and visit 11 of study CTBM100C2303E1 took place not more than 5 days before enrollment into this study.~* Confirmed diagnosis of cystic fibrosis participants with P. aeruginosa infection.~* Forced Expiratory Volume in one second (FEV1) at screening (at start of study CTBM100C2303) must be between 25% and 80% of normal predicted values.~Exclusion Criteria:~* Any use of inhaled anti-pseudomonal antibiotics between the termination of the trial CTMB100C2303E1 and the enrollment into this study.~* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Tobramycin Inhalation Powder (TIPnew) (Type: EXPERIMENTAL): Participants received four capsules of 28 mg TIPnew (112 mg), inhaled twice a day (b.i.d.) in the morning and the evening given in a cycle of 28 days on treatment followed by 28 days off treatment for three consecutive cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Plaque psoriasis for at least 6 months~* Moderate to severe disease~* Candidate for phototherapy or systemic therapy~Exclusion Criteria:~* Other forms of psoriasis~* History of recent infection~* Prior exposure to BMS-986165 or active comparator~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-986165 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Apremilast (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (greater than 18 years old)~* Patients scheduled for primary unilateral knee arthroplasty~* Patients for La Paz- Cantoblanco Hospital, Madrid, Spain~Exclusion Criteria:~* Patients that refuse to sign the Inform Consent~* Allergy to tranexamic acid~* Major comorbidities: Severe ischemic heart disease(class III and IV of New York Heart Association); sleep apnea syndrome; severe EPOC; renal dysfunction (plasma creatinine\>2mg/dL if mens and \>1.8mg/dL if woman); or hepatic disfunction.~* Coagulopathy (preoperative platelet count \<150,000/mm3, INR\>1.4, prolonged PPT(\>1.4 x normal)~* History of thromboembolic disease: CVA, DVT, PE~* Blood dyscrasias~* Retinopathy (disturbances of color vision)~* Jehovah's witnesses~* Pregnancy~* Breastfeeding~* Been participating or been participated a year ago in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): 1. Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:~   * 50mL by irrigation before wound closure~  * 50mL by intraarticular administration (Drenofast) after wound closure.~2. Intravenous administration of Normal saline (0.9% sodium chloride) as follow:~   * 100mL before tourniquet realised~  * 100mL 3 hours after surgery
- Comparator (Type: ACTIVE_COMPARATOR): 1. Topical administration of Normal saline (0.9% sodium chloride) as follow:~   * 50mL by irrigation before wound closure~  * 50mL by intraarticular administration (Drenofast) after wound closure~2. Intravenous administration of two dosis of Tranexamic Acid as follow:~   * 15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised~  * 15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* Have a body mass index between 20.0 to 29.9 kg/m², inclusive.~Exclusion Criteria:~* History and/or current presence of clinical significant atopic allergy, hypersensitivity or allergic reactions, also including known or suspected clinically relevant drug hypersensitivity to any components of the test and reference investigational product formulation or comparable drugs~* Active or latent Tuberculosis or who have a history of Tuberculosis~* History of invasive systemic fungal infections or other opportunistic infections~* Systemic or local infection, a known risk for developing sepsis and/or known active inflammatory process~* Serious infection associated with hospitalisation and/or which required intravenous antibiotics~* History of and/or current cardiac disease~* Have received live vaccine(s) within 4 weeks prior to Screening or who will require live vaccine(s) between Screening and the subject's last visit~* Intake medication with a half-life \> 24 h within 4 weeks or 10 half-lives of the medication prior to investigational product administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Pen of SB5 (Type: EXPERIMENTAL): Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
- PFS of SB5 (Type: ACTIVE_COMPARATOR): PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for Excessive Menstruation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Complaint of HMB, including women with fibroids~* Pre-menopausal~* Age 18 years and over~* Describing menstrual cycles every 21- 42 days~* Provide written informed consent prior to any study related procedures~* If of childbearing potential either agree to practice a non-hormonal method of contraception for duration of study or have a partner with a vasectomy~* Workup (Study 1 or 2)- MBL for single screening period is \>= 50mL~* Adaptive Trial (Study 3)- average MBL for two screening menstrual collections is \>= 50mL~Exclusion Criteria:~* Currently breast-feeding~* History or current uterus, cervix, ovarian or breast cancer~* Known severe coagulation disorder~* Glucocorticoid treatment or sex steroid administration by any route in previous 1 month~* Taking prohibited medication -~* Thyroid, renal or liver dysfunction~* Diabetes mellitus~* Treated moderate/severe hypertension~* Psychotic depressive illness~* Rare hereditary galactose intolerance, lactase deficiency or glucose galactose malabsorption (due to lactose content of trial medication)~* Has a problem with alcohol or drug abuse~* Has a mental condition rendering her unable to understand the nature and scope of the study~* Participation in treatment phase in any earlier DexFEM study (1 or 2)~* Is currently enrolled in an investigational drug or device study or participated in such a study within the previous 30 days and is still in exclusion period~* workup study 1, only, an additional exclusion criterion of any contra-indication to MRI

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* Females of childbearing potential are on approved birth control method~* Negative pregnancy testing for females of childbearing potential~* Previously diagnosed or newly diagnosed with T2DM drug naïve subjects~* HbA1c: 6.7-10%~* Age 18 - 80 years~* BMI ≥ 18.5 kg/m2 and ≤ 40 kg/m2~* Fasting serum glucose \< 300 mg/dL~* Normal liver function, normal thyroid function, no history of liver, biliary or intestinal disease~* Normal TSH~* On stable diet and exercise routine for at least 4 weeks prior to screening~* Has had a stable weight (+/-5%) for ≥3 months before screening~Exclusion Criteria:~* A history of type 1 diabetes mellitus or history of diabetic ketoacidosis~* History of chronic (required daily for \> 2 months) use of insulin therapy~* Treatment with blood pressure lowering therapy that has not been stable for three months before screening~* Treatment with lipid lowering medication other than statins~* Treatment with statins that has not been stable for three months before screening~* Treatment with a DPP-4 inhibitor or and GLP1 agonists at any time~* Treatment with a thiazolidinedione (TZD) within the last 6 months of screening~* History of an allergic or toxic reaction to sitagliptin or colesevelam~* History of dysphagia, swallowing disorders, bowel obstruction, intestinal motility disorder, and gastrointestinal disorders~* History of major gastrointestinal surgery~* History of kidney problems~* Fasting plasma triglycerides \> 300 mg/dL~* Serum LDL-C \<60 mg/dL~* Positive toxicology test~* Known hypersensitivity to colesevelam HCl or sitagliptin.~* Any contraindications to a study medication (colesevelam HCl or sitagliptin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam HCl: 3 tablets, 2x/day (Type: ACTIVE_COMPARATOR): Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
- Colesevelam plus Sitagliptin (Type: ACTIVE_COMPARATOR): Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.~Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete